DDrare: Database of Drug Development for Rare Diseases

162. 類天疱瘡（後天性表皮水疱症を含む。）
［臨床試験数：70，薬物数：117（DrugBank：46），標的遺伝子数：30，標的パスウェイ数：128］

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE; AC-203 1% Topical Ointment; AKST4290; ARAVA; Acetate; Apremilast; Avdoralimab; Avdoralimab (IPH5401); Azathioprine; Azathioprine or Mycophenolate mofetil; BIV009; Benralizumab; Bertilimumab; Blood test; CC; CC-10004; CORTANCYL 20 mg; Carboxymethylcellulose; Cellcept® in autoimmune bullous dermatoses; Cellulose; Clobetasol; Clobetasol 0.05% Topical Ointment; Clobetasol Propionate cream treatment; Clobetasol propionate; Clobetasol propionate + Methotrexate; Clobetasol propionate alone; Collagenase; Cortancyl; Cotton; Cultivated oral mucosal epithelial sheet transplantation; Cyclophosphamide; Cyclophosphamide 50Mg Oral Tablet; Cyclosporine; DERMOVAL; DF2156A; DUPILUMAB; Data report; Dermoval; Device: Carboxymethylcellulose with ionic silver (Aquacel Ag); Device: Cellulose acetate with petrolatum; Device: Cotton gauze with petrolatum; Device: Nanocrystalline silver (Acticoat); Dexamethasone; Dexamethasone 0.5mg/5ml solution; Dexamethasone 0.5mg/5ml solution in Mucolox™; Doxycycline; Dupilumab; Dupixent; Gold; Halometasone; INTERLEUKIN-2; IPH5401; Imatinib; Infliximab; Ixekizumab; Ladarixin; Leflunomide; MABTHERA; MTX; MabThera; Mabthera; Mabthéra; Mathéra; Medrone; Mepolizumab; Mepolizumab (a-IL-5 antibody); Methotrexate; Methylprednisolone; Minocycline; Mometasone; Mometasone furoate; Mycophenolate; Mycophenolate mofetil; Myfortic; Myfortic 180 mg; Myfortic 180 mg Filmtabletten; NNC0215-0384; NPB-01; Nicotinamide; Omalizumab; Oral corticosteroids (OCS); Otezla; Other: Blood sample and cotton skin swabs; Other: Control; PREDNISONE; Petrolatum; Prednisolone; Prednisone; Procedure: Clobetasol propionate; Procedure: Impedance analysis; Procedure: bone densitometry; Procedure: collagenase; Procedure: radiographs of the thoracic and lumbar spine; QGE031; RESTASIS; RITUXIMAB; RVA576; Riboflavin; Rituximab; Rituximab 1g IV; Rituximab combined with Omalizumab; SIMVASTATIN; Silver; Simvastatin; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; Solu-Medrone; Tildrakizumab; Tildrakizumab Prefilled Syringe; Topical infliximab; Treatment systemic therapy (prednisone); Treatment with systemic therapy (doxycycline); Treatment with systemic therapy (methotrexate); Treatment with systemic therapy (prednisone); Treatment with topical superpotent corticosteroid therapy; Tripterygium; Ustekinumab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02837965 (ClinicalTrials.gov)	April 2013	24/6/2016	Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid	Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid	Bullous Pemphigoid	Drug: treatment with topical superpotent corticosteroid therapy;Drug: treatment with systemic therapy (methotrexate);Drug: treatment systemic therapy (prednisone);Drug: treatment with systemic therapy (prednisone);Drug: treatment with systemic therapy (doxycycline)	CHU de Reims	NULL	Recruiting	18 Years	N/A	Both	150	N/A	France
2	ChiCTR-TRC-12003593	2011-08-01	2012-12-30	Use of Oral Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial	Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases	bullous pemphigoid	Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.;	Institute of dermatology; Chinese Academy of Medical Sciences	NULL	Completed	18		Both	Glucocorticoids group:90;Glucocorticoid plus MTX group:90;		China
3	ChiCTR-TRC-12003538	2011-08-01	2012-12-27	Use of inravenous Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial	Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases	Bullous pemphigoid	Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.;	Institute of dermatology, Chinese Academy of Medical Sciences	NULL	Recruiting	18	0	Both	Glucocorticoids group:90;Glucocorticoid plus MTX group:90;		China
4	NCT02313870 (ClinicalTrials.gov)	January 2008	8/12/2014	Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid	Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid	Bullous Pemphigoid	Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone	University Hospital, Montpellier	NULL	Recruiting	18 Years	N/A	Both	300	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02837965
(ClinicalTrials.gov)

April 2013

24/6/2016

Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid

Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid

Bullous Pemphigoid

Drug: treatment with topical superpotent corticosteroid therapy;Drug: treatment with systemic therapy (methotrexate);Drug: treatment systemic therapy (prednisone);Drug: treatment with systemic therapy (prednisone);Drug: treatment with systemic therapy (doxycycline)

CHU de Reims

NULL

Recruiting

18 Years

N/A

Both

150

N/A

France

ChiCTR-TRC-12003593

2011-08-01

2012-12-30

Use of Oral Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial

Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases

bullous pemphigoid

Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.;

Institute of dermatology; Chinese Academy of Medical Sciences

NULL

Completed

Both

Glucocorticoids group:90;Glucocorticoid plus MTX group:90;

China

ChiCTR-TRC-12003538

2011-08-01

2012-12-27

Use of inravenous Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trial

Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases

Bullous pemphigoid

Glucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.;

Institute of dermatology, Chinese Academy of Medical Sciences

NULL

Recruiting

Both

Glucocorticoids group:90;Glucocorticoid plus MTX group:90;

China

NCT02313870
(ClinicalTrials.gov)

January 2008

8/12/2014

Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid

Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid

Bullous Pemphigoid

Drug: clobetasol propionate + Methotrexate;Drug: clobetasol propionate alone

University Hospital, Montpellier

NULL

Recruiting

18 Years

N/A

Both

300

Phase 3

France